ClinicalTrials.gg
CompletedNCT01171807CrocodexUpdated Sep 24, 2024Results posted

Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis

A Phase 2 interventional study of Dex 21-P and Placebo in Ulcerative Colitis, sponsored by Quince Therapeutics S.p.A.. Completed at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-24.

Sponsored by Quince Therapeutics S.p.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 7 years after the study started (first participant enrolled Jul 2003, registered Jul 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 209 studies in Colitis, Ulcerative with a site in Italy — 48 open to participants now, 77 under way, 27 of them phase 3. Colitis, Ulcerative · Italy.

Enrollment
155th of 175
33 · median 182
Started
2003
the only one that year
Phase 2
66 of 209
9 open now
Registered
18th of 209
by date

Among the 209 studies in Colitis, Ulcerative with a site in Italy, this one is the 155th largest by enrollment of the 175 interventional ones that give a count, is the only one that started in 2003, is one of 66 in phase 2, and was the 18th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

48 of the 209 studies in Colitis, Ulcerative with a site in Italy are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 209 studies in Colitis, Ulcerative with a site in Italy, or all of them as a file.
02

Study summary

Objectives:

The primary objective of this trial was to evaluate the patients response rate at the end of the study.

Patients were considered responder if one of the following conditions occurs:

  • Disease remission (Powell Tuck ≤ 3 or CDAI \< 150) and withdrawal of oral steroids therapy from at least the second treatment procedure;
  • Disease marked improvement versus basal conditions (at least 5 point decrease in Powell Tuck index or 150 point decrease in CDAI score) and withdrawal of oral steroids therapy from at least the second treatment procedure.

Secondary objectives:

  • to evaluate the endogenous cortisole production after receiving the study treatment
  • to evaluate the inflammatory indexes (ESR and CPR) after receiving the study treatment
  • to evaluate the endoscopic remission in patients suffering from mesalazine refractory Ulcerative Colitis
  • to evaluate the safety of dexamethasone intra-erythrocyte therapy with particular attention to steroid-related adverse events.
Read the detailed description

This was a single-center, placebo-controlled, randomised, phase II explorative study with the aim to investigate the ability of the new steroid delivery system to induce or maintain remission in steroid-dependent or mesalazine refractory patients suffering from Chron's disease (CD) or Ulcerative Colitis (UC) .

Once the patient was deemed eligible for the study, the treatment plan was selected as follows

In the Dexamethasone arm (DEX 21-P):

  • steroid-dependant patients: one treatment procedure every 30 days up to a total of 6 procedures
  • mesalazine refractory active UC patients: one treatment procedure every 15 days up to a total of 3 procedures.

In the placebo arm:

Patients assigned to placebo arm performed the same procedure as the patients assigned to the DEX 21-P group without loading in the Red Blood Cells the Dex 21-P.

The planned duration of individual patient participation in the study was a maximum of 6 or 28 weeks, depending from the assigned treatment scheme.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative colitis
  • Steroid-dependency
  • Steroid adverse events
  • Erythrocytes
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. More than 18 years of age
  2. Patients suffering from one of the following chronic inflammatory intestinal disease:

    • -dependent Chron's Disease or Ulcerative Colitis following ECCO definition or mild-moderate active UC ( Powell Tuck between 3 and 14- an index of 14 was allowed; endoscopic Baron score >1) to mesalazine.
  3. Disease extension over the rectum (at least 15 cm) in patients suffering from Ulcerative Colitis
  4. Patients willing and be able to give written .

Exclusion criteria

Exclusion Criteria:

  1. Intestinal sub occlusion or a suspected abdomen abscess or a severe degree of the disease (CDAI > 450) in patient suffering from Chron's Disease
  2. Patient affected by a severe Ulcerative Colitis (more than 6 evacuations of liquid, mucous-blooding stools combined at least one systemic sign as body temperature > 37.8 °C, heart rate \< 90 bpm, ESR > 30 mm/h or \< 10.5 g/dL)
  3. Severe concurrent disease(s) as:

    • Medullar deficit: white blood cells \< 3000/mm3; \< 75000/mm3; haemoglobin \< 10 g/dL;
    • Hepatic diseases presenting total ≥ 3 mg/dL; (GOT) ≥ 5 UNL; alkaline phosphatase ≥ 5 UNL:
    • Renal failure with serum creatinine ≥ 3 mg/dL;
    • Heart failure
    • Respiratory failure
    • Disabling neurological diseases
    • Neoplasia
    • Patient deemed candidate to surgery due to Chron's Disease or Ulcerative Colitis
    • Chronic alcohol or drug abuse
    • Patient for whom the use of is (e.g. systemic infections)
  4. Treatment with Infliximab in the previous 4 months
  5. Pregnant woman or female for whom the possibility of a pregnancy during the study could not be excluded.
  6. Non-collaborating patient or subject unable to regularly undergo the scheduled study procedures.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Dex 21-P

    In this arm a dose of 20 ml of Dex 2-P solution was administered every 15 or 30 days for a total of 3 or 6 treatment procedures, respectively. Specifically, steroid-dependant IBD patients had to undergo a total of 6 procedures at one month interval, while active mesalazine refractory UC patients had to undergo a total of 3 procedures at 15 days interval. Every procedure implies the collection and re-infusion of autologous erythrocytes previously loaded with Dex 21-P.

    Drug: Dex 21-P

  • Placebo comparator
    Placebo

    In this arm placebo solution was administered every 15 or 30 days for a total of 3 or 6 treatment procedures, respectively. Specifically, steroid-dependant IBD patients had to undergo a total of 6 procedures at one month interval, while active mesalazine refractory UC patients had to undergo a total of 3 procedures at 15 days interval. Every procedure implies the collection and re-infusion of autologous erythrocytes previously NOT loaded with Dex21-P.

    Drug: Placebo

Interventions

  • At each procedure 50 ml of patient whole blood was washed with saline solution and centrifugated. The isolated erythrocytes were suspended into 2 hypotonic solutions to make their membrane permeable and incubated with Dex 21-P sodium salt up to obtain a final concentration of 10 mM. The drug loaded erythrocytes were immediately re-infused by using a suitable filter.

    Also known as: Dexamethasone 21-phosphate

  • DrugPlacebo

    Patients assigned to placebo arm performed the same procedure as the patients assigned to the DEX 21-P group without loading in the Red Blood Cells the Dex 21-P

06

What researchers measure

Primary outcomes

  1. The Proportion of Patients Responders to Dex 21-P vs Placebo

    Patients were considered responder if, at the EoS, one of the following occurred: * Disease remission (Powell Tuck index ≤ 3 or CDAI \< 150) and withdrawal of oral steroids therapy from at least the second treatment procedure; * Disease marked improvement vs basal conditions (at least 5 point decrease in Powell Tuck or 150 point decrease in CDAI score) and withdrawal of oral steroids therapy from at least the second treatment procedure. The Powell-Tuck index was calculated by adding the subscores given by 7 items. A total score \< 10 indicated a mild activity of the UC, and a total score \>14 a severe one. The higher the score the worse the outcome. Crohn Disease Activity Index (CDAI) was a tool that combines subjective parameters, with objectives parameters. The score given to each parameter was inserted in an algorithm which provided the final Index value. A moderate CD showed a CDAI score between 220 and 450, while a CDAI \> 450 was an activity index indicating a severe disease.

    Time frame: From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)

Secondary outcomes

  1. Change From Baseline in Endogenous Cortisole Blood Level After Receiving the Study Treatment

    Blood levels of endogenous cortisol were determined before the first and 15 days/one month after the last intra-erythrocytes infusion, according to the assigned treatment scheme planned for each patient. As steroids suppress ACTH production resulting in lowering cortisol levels, the assessment of this parameter was intended to investigate the ability of the dexamethasone intra-erythrocytes administration in minimising this steroid adverse effect. In child, from 1 to 16 years, the total serum cortisol reference range is 5-23 mcg/dL at 8 am, and 3-13 mcg/dL at 4 pm.

    Time frame: From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)

  2. Change From Baseline in Inflammatory Indexes After Receiving the Study Treatment: Erythrocyte Sedimentation Rate (ESR)

    The erythrocyte sedimentation rate (ESR) is the rate at which red blood cells in anticoagulated whole blood descend in a standardized tube over a period of one hour. It is a common hematology test, and is a non-specific measure of inflammation. To perform the test, anticoagulated blood is traditionally placed in an upright tube (Westergren tube) and the distance which the red blood cells fall is measured and reported in millimetres at the end of one hour. ESR was evaluated as supportive data for the assessment of the intestinal disease severity. It was determined before the first and 15 days/one month after the last intra-erythrocytes infusion, according to the assigned treatment scheme planned for each patient. ESR normal values in blood were from 0 to 20 mm/hour. Higher values are considered abnormal both in adults and in children. For ESR values \> 100 mm/hour, there is a high probability that an underlying cause would be found upon investigation.

    Time frame: From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)

  3. Change From Baseline in Inflammatory Indexes After Receiving the Study Treatment: C-reactive Protein (CRP)

    CRP is a protein produced by the liver. A C-reactive protein test measures the level of C-reactive protein (CRP) in a blood sample. Normal levels of blood C-reactive protein are low (0.3 to 1.0 mg/L). In case of inflammation liver releases more CRP into your bloodstream: results equal to or greater than 8 mg/L or 10 mg/L are considered high. High levels of CRP may indicate a serious health condition that causes inflammation. C-reactive protein (CRP) was determined before the first and 15 days/one month after the last intra-erythrocytes infusion, according to the assigned treatment scheme planned for each patient. Inflammation parameters (CRP) were evaluated as supportive data for the assessment of the intestinal disease severity. C-reactive protein was measured in milligrams per liter (mg/L). Results equal to or greater than 8 mg/L or 10 mg/L were considered high.

    Time frame: From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)

  4. Count of Partecipants, Suffering From Mesalazine Refractory UC, With Modification in Endoscopic Result (Baron Score)

    The Baron score was an endoscopic grading system for ulcerative colitis. Four grades are defined (0-3) by the Baron score according to the severity of macroscopic inflammation of the rectal mucosal appearances at rigid sigmoidoscopy: 0 = normal mucosa (ramifying vascular pattern clearly visible, no spontaneous bleeding, no bleeding to light touch); 1. = abnormal mucosa but non-haemorrhagic appearances between scores 0 and 2; 2. = moderately haemorrhagic (bleeding to light touch, but no spontaneous bleeding seen ahead of the instrument on initial inspection); 3= severely haemorrhagic (spontaneous bleeding seen ahead of instrument at initial inspection and bleeds to light touch). The higher the score the worst the outcome. Due to the nature of the score, its assessment was limited to patients suffering from UC, only. (CD or UC steroid-dependant patients were planned to receive the study treatment procedure every 30 days for a total of 6 administrations)

    Time frame: From baseline to End of treatment = 28 weeks ± 5 days (in mesalazine refractory UC patients)

  5. Number of Patients Experiencing at Least One TEAE (Not Steroid-related)

    At each access to the clinic (except at the baseline visit one), patients were questioned and/or examined for evidence of adverse events. An adverse event was defined as any untoward medical occurrence or unfavourable and unintended sign in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, whether or not considered related to the use of that product. This includes the onset of new illness and the exacerbation of pre-existing conditions.

    Time frame: From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)

  6. Number of Patients Experiencing at Least One TEAE (Steroid-related)

    Steroid related adverse events were investigated to assess the ability of the therapeutic approach under study in reducing the occurrence or entity of steroid adverse effects.

    Time frame: From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)

07

Results

Posted Sep 24, 2024

Participant flow

The total size of 40 patients was originally selected. However the final sample size of 33 was considered reasonable for the purpose of the study , due to the explorative nature of the protocol. Patients were assigned to a treatment plan consisting of a treatment procedure every 15 or 30 days for a total of 3 or 6 procedures, respectively.

Participant flow — Overall Study
MilestoneDex 21-PPlacebo
Started2112
Intention to treat (itt) population2112
Per protocol (pp) population1811
Safety (saf) population2112
Completed158
Not completed64
Withdrew: Treatment failure24
Withdrew: Non compliance10
Withdrew: Lost to follow-up30

Outcome measures

PrimaryThe Proportion of Patients Responders to Dex 21-P vs Placebo

Patients were considered responder if, at the EoS, one of the following occurred: * Disease remission (Powell Tuck index ≤ 3 or CDAI \< 150) and withdrawal of oral steroids therapy from at least the second treatment procedure; * Disease marked improvement vs basal conditions (at least 5 point decrease in Powell Tuck or 150 point decrease in CDAI score) and withdrawal of oral steroids therapy from at least the second treatment procedure. The Powell-Tuck index was calculated by adding the subscores given by 7 items. A total score \< 10 indicated a mild activity of the UC, and a total score \>14 a severe one. The higher the score the worse the outcome. Crohn Disease Activity Index (CDAI) was a tool that combines subjective parameters, with objectives parameters. The score given to each parameter was inserted in an algorithm which provided the final Index value. A moderate CD showed a CDAI score between 220 and 450, while a CDAI \> 450 was an activity index indicating a severe disease.

Time frame:
From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)
Reported as:
Count of participants · Participants
The Proportion of Patients Responders to Dex 21-P vs Placebo
ParticipantsDex 21-P - ITTPlacebo - ITT
Responders151
Non Responders611
Statistical analysis
  • Dex 21-P - ITT vs Placebo - ITT · Chi-squared · p = <0.001
SecondaryChange From Baseline in Endogenous Cortisole Blood Level After Receiving the Study Treatment

Blood levels of endogenous cortisol were determined before the first and 15 days/one month after the last intra-erythrocytes infusion, according to the assigned treatment scheme planned for each patient. As steroids suppress ACTH production resulting in lowering cortisol levels, the assessment of this parameter was intended to investigate the ability of the dexamethasone intra-erythrocytes administration in minimising this steroid adverse effect. In child, from 1 to 16 years, the total serum cortisol reference range is 5-23 mcg/dL at 8 am, and 3-13 mcg/dL at 4 pm.

Time frame:
From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)
Reported as:
Mean · mcg/dL
Change From Baseline in Endogenous Cortisole Blood Level After Receiving the Study Treatment
mcg/dLDex 21-P - ITTPlacebo - ITT
Change From Baseline in Endogenous Cortisole Blood Level After Receiving the Study Treatment3.3 ± 2.122.3 ± 5.71
SecondaryChange From Baseline in Inflammatory Indexes After Receiving the Study Treatment: Erythrocyte Sedimentation Rate (ESR)

The erythrocyte sedimentation rate (ESR) is the rate at which red blood cells in anticoagulated whole blood descend in a standardized tube over a period of one hour. It is a common hematology test, and is a non-specific measure of inflammation. To perform the test, anticoagulated blood is traditionally placed in an upright tube (Westergren tube) and the distance which the red blood cells fall is measured and reported in millimetres at the end of one hour. ESR was evaluated as supportive data for the assessment of the intestinal disease severity. It was determined before the first and 15 days/one month after the last intra-erythrocytes infusion, according to the assigned treatment scheme planned for each patient. ESR normal values in blood were from 0 to 20 mm/hour. Higher values are considered abnormal both in adults and in children. For ESR values \> 100 mm/hour, there is a high probability that an underlying cause would be found upon investigation.

Time frame:
From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)
Reported as:
Mean · mm/h
Change From Baseline in Inflammatory Indexes After Receiving the Study Treatment: Erythrocyte Sedimentation Rate (ESR)
mm/hDex 21-P - ITTPlacebo - ITT
Change From Baseline in Inflammatory Indexes After Receiving the Study Treatment: Erythrocyte Sedimentation Rate (ESR)-4.9 ± 25.88-9.3 ± 15.44
SecondaryChange From Baseline in Inflammatory Indexes After Receiving the Study Treatment: C-reactive Protein (CRP)

CRP is a protein produced by the liver. A C-reactive protein test measures the level of C-reactive protein (CRP) in a blood sample. Normal levels of blood C-reactive protein are low (0.3 to 1.0 mg/L). In case of inflammation liver releases more CRP into your bloodstream: results equal to or greater than 8 mg/L or 10 mg/L are considered high. High levels of CRP may indicate a serious health condition that causes inflammation. C-reactive protein (CRP) was determined before the first and 15 days/one month after the last intra-erythrocytes infusion, according to the assigned treatment scheme planned for each patient. Inflammation parameters (CRP) were evaluated as supportive data for the assessment of the intestinal disease severity. C-reactive protein was measured in milligrams per liter (mg/L). Results equal to or greater than 8 mg/L or 10 mg/L were considered high.

Time frame:
From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)
Reported as:
Mean · mg/L
Change From Baseline in Inflammatory Indexes After Receiving the Study Treatment: C-reactive Protein (CRP)
mg/LDex 21-P - ITTPlacebo - ITT
Change From Baseline in Inflammatory Indexes After Receiving the Study Treatment: C-reactive Protein (CRP)-0.5 ± 4.35-2.2 ± 7.27
SecondaryCount of Partecipants, Suffering From Mesalazine Refractory UC, With Modification in Endoscopic Result (Baron Score)

The Baron score was an endoscopic grading system for ulcerative colitis. Four grades are defined (0-3) by the Baron score according to the severity of macroscopic inflammation of the rectal mucosal appearances at rigid sigmoidoscopy: 0 = normal mucosa (ramifying vascular pattern clearly visible, no spontaneous bleeding, no bleeding to light touch); 1. = abnormal mucosa but non-haemorrhagic appearances between scores 0 and 2; 2. = moderately haemorrhagic (bleeding to light touch, but no spontaneous bleeding seen ahead of the instrument on initial inspection); 3= severely haemorrhagic (spontaneous bleeding seen ahead of instrument at initial inspection and bleeds to light touch). The higher the score the worst the outcome. Due to the nature of the score, its assessment was limited to patients suffering from UC, only. (CD or UC steroid-dependant patients were planned to receive the study treatment procedure every 30 days for a total of 6 administrations)

Time frame:
From baseline to End of treatment = 28 weeks ± 5 days (in mesalazine refractory UC patients)
Reported as:
Count of participants · Participants
Count of Partecipants, Suffering From Mesalazine Refractory UC, With Modification in Endoscopic Result (Baron Score)
ParticipantsDex 21-P - ITTPlacebo - ITT
From 0 to 0 score10
From 1 to 0 score01
From 1 to 1 score02
From 1 to 2 score30
From 2 to 1 score03
From 2 to 2 score21
From 3 to 1 score20
From 3 to 2 score11
From 3 to 3 score20
SecondaryNumber of Patients Experiencing at Least One TEAE (Not Steroid-related)

At each access to the clinic (except at the baseline visit one), patients were questioned and/or examined for evidence of adverse events. An adverse event was defined as any untoward medical occurrence or unfavourable and unintended sign in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, whether or not considered related to the use of that product. This includes the onset of new illness and the exacerbation of pre-existing conditions.

Time frame:
From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)
Reported as:
Count of participants · Participants
Number of Patients Experiencing at Least One TEAE (Not Steroid-related)
ParticipantsDex 21-P - SAFPlacebo - SAF
Patients experiencing at least one TEAE118
Patients experiencing at least one serious AE01
SecondaryNumber of Patients Experiencing at Least One TEAE (Steroid-related)

Steroid related adverse events were investigated to assess the ability of the therapeutic approach under study in reducing the occurrence or entity of steroid adverse effects.

Time frame:
From baseline to End of treatment = 6 weeks ± 10 days (in chronic and steroid dependent IBD patients) or 28 weeks ± 5 days (in mesalazine refractory UC patients)
Reported as:
Count of participants · Participants
Number of Patients Experiencing at Least One TEAE (Steroid-related)
ParticipantsDex 21-P - SAFPlacebo - SAF
Number of Patients Experiencing at Least One TEAE (Steroid-related)33

Adverse events

Collected over TEAEs were assessed throughout the study (except at the baseline visit 1) at each access to the clinic. More specifically adverse events were assessed: - steroid-dependant patients: every 30 days up to month 6 (Final Visit) - mesalazine refractory active UC patients: every 15 days up to 45 days (Final Visit). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dex 21-P - SAF0/21 (0%)0/21 (0%)11/21 (52.4%)
Placebo - SAF0/12 (0%)1/12 (8.3%)8/12 (66.7%)
Most frequent serious events
Most frequent serious events
EventDex 21-P - SAFPlacebo - SAF
Acute pancreatitisGastrointestinal disorders0/211/12
Most frequent other events
Showing 10 of 25
Most frequent other events
EventDex 21-P - SAFPlacebo - SAF
Abdominal painGastrointestinal disorders4/210/12
RectorrhageGastrointestinal disorders0/212/12
Evacuations increaseGastrointestinal disorders0/212/12
Increase of lipaseInvestigations2/210/12
EpigastralgiaGastrointestinal disorders2/211/12
ErythemaSkin and subcutaneous tissue disorders2/210/12
Articular painMusculoskeletal and connective tissue disorders2/210/12
Increase of alkaline phosphataseInvestigations0/211/12
Joint aspirationInvestigations0/211/12
DyspepsiaGastrointestinal disorders0/211/12

Baseline characteristics

Intention to Treat population (ITT): subjects who underwent at least one treatment procedure

Age, Continuous
Age, Continuous(years)Dex 21-P - ITTPlacebo - ITTTotal
Mean43 ± 10.140 ± 13.242 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Dex 21-P - ITTPlacebo - ITTTotal
Female10616
Male11617
Region of Enrollment
Region of Enrollment(participants)Dex 21-P - ITTPlacebo - ITTTotal
Italy211233
08

Study locations

1 site
  • Casa Sollievo della Sofferenza Hospital
    San Giovanni Rotondo, 71013, Italy
09

References and documents

Publications

  • Bossa F, Annese V, Valvano MR, Latiano A, Martino G, Rossi L, Magnani M, Palmieri O, Serafini S, Damonte G, De Santo E, Andriulli A. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis. 2013 Aug;19(9):1872-9. doi: 10.1097/MIB.0b013e3182874065. PubMed 23714676 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2003 to primary completion in May 2007, 45 months.

Results were first posted in Sep 2024, 17 years 4 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 45 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2010
First posted
Jul 29, 2010
StartActual
Jul 22, 2003
Primary completionActual
May 15, 2007
CompletionActual
May 15, 2007
Results first posted
Sep 24, 2024
Last update
Sep 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01171807
Lead sponsor
Quince Therapeutics S.p.A.
Collaborators
Casa Sollievo della Sofferenza IRCCS
Responsible party
Sponsor
First posted
Jul 29, 2010
Start date
Jul 22, 2003
Primary completion
May 15, 2007
Completion
May 15, 2007
Results posted
Sep 24, 2024
Last update
Sep 24, 2024

Study contacts

Angelo Andriulli, MD
principal investigator · Casa Sollievo della Sofferenza Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion